Allergic rhinitis is a collection of symptoms, mostly in the nose and eyes that occur as a result of the inhalation of an allergen such as dust or pollen. It is currently among the top five chronic medical conditions, estimated to affect between 10% to 30% of adults and 40% of children. In each of the last three decades, there has been a 100% increase in the prevalence of allergic rhinitis in developed countries. In 2012, over 50 million prescriptions were dispensed to treat nasal allergies in the United States.
TBS-6 – Allergic Rhinitis
TBS-6 is in early stage exploratory development. It is intended to provide patients suffering from seasonal and perennial allergic rhinitis with leading nasally delivered corticosteroids. Current treatments result in side effects due to the delivery of the active ingredient by a nasal spray pump. Use of the TriVair™ technology to deliver TBS-6 may provide a superior outcome for the patient by achieving targeted delivery of the medication by causing the soft palate to close when exhaling into the TriVair™ dispenser.